Free Trial

Structure Therapeutics (GPCR) Stock Forecast & Price Target

Structure Therapeutics logo
$33.42 -0.32 (-0.95%)
(As of 01:26 PM ET)

Structure Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
6

Based on 6 Wall Street analysts who have issued ratings for Structure Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for GPCR.

Consensus Price Target

$86.80
159.72% Upside
According to the 6 analysts' twelve-month price targets for Structure Therapeutics, the average price target is $86.80. The highest price target for GPCR is $118.00, while the lowest price target for GPCR is $65.00. The average price target represents a forecasted upside of 159.72% from the current price of $33.42.
Get the Latest News and Ratings for GPCR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Structure Therapeutics and its competitors.

Sign Up

GPCR Analyst Ratings Over Time

TypeCurrent Forecast
11/28/23 to 11/27/24
1 Month Ago
10/29/23 to 10/28/24
3 Months Ago
8/30/23 to 8/29/24
1 Year Ago
11/28/22 to 11/28/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$86.80$86.80$84.63$81.14
Forecasted Upside159.72% Upside131.84% Upside120.84% Upside50.01% Upside
Consensus Rating
Buy
Buy
Buy
Buy

GPCR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GPCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Structure Therapeutics Stock vs. The Competition

TypeStructure TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside157.26% Upside25,238.49% Upside6.72% Upside
News Sentiment Rating
Positive News

See Recent GPCR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/23/2024Cantor Fitzgerald
3 of 5 stars
P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00+55.06%
9/23/2024Morgan Stanley
3 of 5 stars
 Initiated CoverageOverweight$118.00+181.49%
8/9/2024JMP Securities
2 of 5 stars
 Lower TargetMarket Outperform ➝ Market Outperform$91.00 ➝ $86.00+157.02%
6/7/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$83.00 ➝ $100.00+86.64%
5/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$65.00+81.67%
2/27/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Belghiti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
10/26/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$58.00 ➝ $93.00+32.38%
10/2/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$50.00 ➝ $92.00+58.76%
9/29/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$46.00 ➝ $97.00+92.38%
9/29/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$50.00 ➝ $79.00+58.35%
2/28/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$33.00+37.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:52 PM ET.


GPCR Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Structure Therapeutics is $86.80, with a high forecast of $118.00 and a low forecast of $65.00.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Structure Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GPCR shares.

According to analysts, Structure Therapeutics's stock has a predicted upside of 159.72% based on their 12-month stock forecasts.

Structure Therapeutics has been rated by research analysts at Cantor Fitzgerald, and Morgan Stanley in the past 90 days.

Analysts like Structure Therapeutics more than other "medical" companies. The consensus rating for Structure Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GPCR compares to other companies.


This page (NASDAQ:GPCR) was last updated on 11/27/2024 by MarketBeat.com Staff
From Our Partners